13:00 Tue 02 Jul 2019
Shield Therapeutics - Additional Listing
("Shield" or the "Group")
Additional Listing
Application has been made to the
Following admission, the Company's issued share capital will comprise 117,188,657 ordinary Shares and each Ordinary Share carries one vote. There are no Ordinary Shares held in treasury and accordingly, the total number of voting rights is 117,188,657. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the
- Ends -
For further information please contact:
|
|
|
+44 (0)20 7186 8500 |
|
|
|
|
Nominated Advisor and Broker |
|
|
|
|
+44 (0)20 7418 8900 |
Joint Broker finnCap Ltd |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus / Lianne Cawthorne |
+44 (0)7980 541 893 / +44 (0)7584 391 303 |
About
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE